Treatment of benign prostatic hyperplasia in patients with cardiovascular disease

Vincent M. Santillo, Franklin C. Lowe

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


Pharmacological management is the most common therapeutic approach for patients with benign prostatic hyperplasia and α-adrenoceptor antagonists are the most commonly prescribed initial treatment. Although all of the α-adrenoceptor antagonists produce similar improvements in symptom scores and urinary flow rates, they have different adverse effect profiles, especially with respect to the cardiovascular system. The older α-adrenoceptor antagonists, terazosin and doxazosin, were initially approved for the treatment of hypertension and are associated with higher rates of dizziness, syncope and hypotension than the newer agents, tamsulosin and alfuzosin. The older α-adrenoceptor antagonists are also involved in more interactions and have a greater number of precautions concerning their usage with other cardiovascular medications. Of the newer α-adrenoceptor antagonists, tamsulosin has a lower rate of dizziness than alfuzosin. However, both of these agents are superior to doxazosin and terazosin in that no dose escalation or titration is needed for them.

Original languageEnglish (US)
Pages (from-to)795-805
Number of pages11
JournalDrugs and Aging
Issue number10
StatePublished - 2006
Externally publishedYes

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Pharmacology (medical)


Dive into the research topics of 'Treatment of benign prostatic hyperplasia in patients with cardiovascular disease'. Together they form a unique fingerprint.

Cite this